Search results
US FDA approves Moderna’s RSV vaccine, its second marketed product
WHTC 1450 Holland· 5 days agoBy Patrick Wingrove (Reuters) - The U.S. Food and Drug Administration has approved Moderna's...
FDA Advisers Urge Targeting JN.1 Strain in Recipe for Fall's COVID Vaccines
US News & World Report· 3 hours agoGovernment advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving ...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
CNBC· 5 days agoThe Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial...
Moderna's RSV vaccine for older adults approved
Axios· 5 days agoWhy it matters: It's Moderna's second approved product, and company officials said it's the first mRNA vaccine approved for a disease other than COVID-19...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 3 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
Moderna rises on FT report about bird flu vaccines By Investing.com
Investing.com· 7 days agoShares of Moderna (NASDAQ:MRNA) are up 2.8% premarket Thursday after a report from The Financial...
FDA approves Moderna’s mRNA RSV vaccine for older adults - ABC17NEWS
ABC17 NEWS· 5 days agoThe shot, made by Moderna and sold under the name of mResvia, could be another tool in the country’s RSV arsenal in the fall. Moderna’s shot is the third ...
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
Reuters· 13 hours agoCOVID-19 vaccine makers said data from animals studies showed their 2024-25 shots targeting the JN.1...
COVID Shots for JN.1 Variant Neutralize Newer Strains, Vaccine Makers Say
US News & World Report· 13 hours agoFood and Drug Administration's advisers on Wednesday. The FDA panel will vote to recommend if companies should target the JN.1 variant when the companies update their vaccines